JAK/TYK2
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Dr. John Cush RheumNow
4 years ago
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate)
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read more...
https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
Dr. John Cush RheumNow
4 years ago
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC)
Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021.
https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.
EnvisionRheumat ERheumat
4 years ago
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM
https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS
⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12
#EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Paul Studenic Stiddyo
4 years ago
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear.
Head to head JAK-i vs. non-TNFi interesting
Brilliant developing discussion
number needed to harm vs. number needed to treat
#EULAR2021 @RheumNow
Janet Pope Janetbirdope
4 years ago
tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. Deficiency of TYK2 gives less autoimmune diseases. @RheumNow @eular_org #EULAR2021 BMS Tyk Talk symposium https://t.co/knP9n0Qc0u
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
4 years ago
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
David Liew drdavidliew
4 years ago
Looking at those results (distributed evenly each side of 'maybe a little') it seems we're collectively uncertain right now about what JAK1 selectivity really means in practice.
Hopefully we get stronger clinical insights (toxicity/efficacy) in coming years!
#EULAR2021 @RheumNow https://t.co/jFhVGqpOnb
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.
Poster Hall